Cytotoxic T lymphocyte cell therapy directed against EBV PTLD in the central nervous system
Clinical outcomes of patients with EBV-PTLD who fail rituximab following HSCTПодробнее
Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD)Подробнее
The treatment and management of PTLDПодробнее
PTLDПодробнее
New T cell–based immunotherapy shows promise for lethal stem cell transplant complicationПодробнее
Atara BiotherapeuticsПодробнее
Tabelecleucel in the treatment of EBV+ PTLDПодробнее
Mohamad Mohty, ASH 2018 – Epstein-Barr virus and cytotoxic T lymphocyte therapyПодробнее
Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLDПодробнее
Tab-cel for solid organ or allogeneic transplant recipients with EBV-PTLDПодробнее
Post-Transplant Lymphoproliferative Disorder (PTLD)Подробнее
Cancer Treatment: Isolation & Expansion Of Cytotoxic Killer T CellsПодробнее
Allogeneic therapy for the treatment of refractory hematological malignanciesПодробнее
Improving virus-specific T-cell therapyПодробнее
Transplants and MRD negativity: key themes at IMWПодробнее
Post-Transplant Lymphoproliferative Disease Externally-Led Patient-Focused Drug Development MeetingПодробнее
Tabelecleucel in EBV-associated PTLDПодробнее
Post-Transplant LymphoproliferativeDdisorder (PTLD)Подробнее
Dr. Prockop Discusses Tabelecleucel in Post-Transplant EBV+ LymphomasПодробнее
